Travere Positioned To Seek Accelerated Approval In Rare Kidney Disorder

 
• By Joseph Haas
  
Human kidney on scientific background. 3d illustration
Travere's sparsentan is one of several candidates to be the first approved IgAN therapy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D